The safer management of pediatric ECMO with TEG6s
Not Applicable
Recruiting
- Conditions
- Heart FailureD006333
- Registration Number
- JPRN-jRCT1012220032
- Lead Sponsor
- Sakai Wataru
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 34
Inclusion Criteria
children less than 10 years old, who require ECMO
Exclusion Criteria
crinical confounder including extereme low birth weigh or ECMO device failure etc
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Brain or tracheal hemorrage or circuit closing of ECMO
- Secondary Outcome Measures
Name Time Method mortality
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does TEG6s utilize to optimize anticoagulation in pediatric ECMO patients with heart failure?
How does TEG6s-guided anticoagulation compare to standard protocols in reducing bleeding/clotting events in pediatric ECMO for heart failure?
Which biomarkers predict response to TEG6s-based anticoagulation management in pediatric ECMO for D006333 heart failure?
What adverse events are reported with TEG6s in pediatric ECMO and how do they compare to heparin-based monitoring strategies?
Are there combination therapies or alternative anticoagulants that enhance TEG6s efficacy in pediatric ECMO for heart failure management?